Autolus Therapeutics PLC (AUTL)
4.40
+0.33
(+8.11%)
USD |
NASDAQ |
May 17, 16:00
4.40
0.00 (0.00%)
After-Hours: 20:00
Autolus Therapeutics SG&A Expense (Quarterly): 15.73M for Dec. 31, 2023
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 15.73M |
| September 30, 2023 | 10.61M |
| June 30, 2023 | 11.12M |
| March 31, 2023 | 9.284M |
| December 31, 2022 | 7.412M |
| September 30, 2022 | 8.231M |
| June 30, 2022 | 8.269M |
| March 31, 2022 | 7.987M |
| December 31, 2021 | 7.591M |
| September 30, 2021 | 8.299M |
| Date | Value |
|---|---|
| June 30, 2021 | 7.237M |
| March 31, 2021 | 8.738M |
| December 31, 2020 | 9.006M |
| September 30, 2020 | 9.843M |
| June 30, 2020 | 8.509M |
| March 31, 2020 | 7.614M |
| December 31, 2019 | 9.921M |
| September 30, 2019 | 8.605M |
| June 30, 2019 | 11.37M |
| March 31, 2019 | 9.556M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
7.237M
Minimum
Jun 2021
15.73M
Maximum
Dec 2023
9.230M
Average
8.605M
Median
Sep 2019
SG&A Expense (Quarterly) Benchmarks
| Adaptimmune Therapeutics PLC | 19.73M |
| Biodexa Pharmaceuticals Plc | -- |
| NuCana PLC | 1.597M |
| TC BioPharm (Holdings) PLC | -- |
| Mereo BioPharma Group PLC | 5.906M |